2.1% (consistent with weight loss rate) No Safety Signals: No increased risk of pancreatitis, thyroid tumors, or major CV events Historic Achievement: REDEFINE-1 demonstrated that CagriSema produces the highest mean weight loss (22.7%) ever reported for an obesity pharmacotherapy in a Phase 3 trial
RTA weight loss injections are an investigational medication for the treatment of obesity that functions as a triple hormone receptor agonist (GIP, GLP-1, and glucagon)
Zerbinati C, Caponecchia L, Rago R, et al
It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists , which work by mimicking a naturally occurring hormone that regulates appetite and food intake
More specifically, it is intended for individuals with a body mass index (BMI) above 30 kg/m2 (obese) or those with a BMI of 27 kg/m2 or greater (overweight) who have at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia
Moving beyond broad antioxidant approaches, research must prioritize more precise target identification and validation within the complex oxidative stress network
